C&T Dream failed CGMP (current good manufacturing practice) for its over-the-counter Dry Skin Healing Ointment, including identity testing and process validation.
What happened
FDA inspected the drug manufacturing facility from November 6 to 10, 2023. Investigators found no adequate identity testing of incoming components, including glycerin, for diethylene glycol or ethylene glycol; no adequate process validation; and water damage, a mold-like substance, and an active ceiling leak in the research and development building. FDA said the firm did not respond to the inspection findings form (Form FDA 483) with corrective actions and cited similar observations from a 2017 inspection.
What FDA found
The firm did not test each incoming component lot for identity, including glycerin, to detect diethylene glycol or ethylene glycol contamination.
21 CFR 211.84(d)(1)The firm did not adequately validate its production and process controls to show it can consistently manufacture the OTC drug with defined quality.
21 CFR 211.100(a)The firm did not keep its research and development building in good repair; FDA saw water damage, a mold-like substance, and an active ceiling leak.
21 CFR 211.58
What FDA wants
FDA tells the firm to correct the violations promptly and respond in writing within 15 working days with what it has done and how it will prevent recurrence. FDA also asks the firm to clarify whether it will resume U.S. drug manufacturing and to notify FDA before resuming or moving operations, and recommends a qualified CGMP consultant.
Who should pay attention
- brands that buy OTC topical drug products from this contract manufacturer
- distributors and importers of foreign-made OTC drugs
- suppliers of glycerin and other high-risk drug components
This is a summary. Read the original letter on fda.gov.